Cresset Asset Management LLC Has $973,000 Holdings in Lantheus Holdings, Inc. $LNTH

Cresset Asset Management LLC trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 58.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,882 shares of the medical equipment provider’s stock after selling 16,922 shares during the period. Cresset Asset Management LLC’s holdings in Lantheus were worth $973,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of LNTH. Marshall Wace LLP boosted its holdings in Lantheus by 90.3% in the second quarter. Marshall Wace LLP now owns 183,342 shares of the medical equipment provider’s stock worth $15,008,000 after acquiring an additional 86,994 shares in the last quarter. Baird Financial Group Inc. increased its stake in Lantheus by 22.6% during the 2nd quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock valued at $222,000 after purchasing an additional 500 shares in the last quarter. First Trust Advisors LP increased its stake in Lantheus by 37.4% during the 2nd quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock valued at $5,714,000 after purchasing an additional 19,008 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after buying an additional 698 shares during the last quarter. Finally, Harbor Advisors LLC lifted its stake in shares of Lantheus by 60.0% in the second quarter. Harbor Advisors LLC now owns 4,000 shares of the medical equipment provider’s stock valued at $327,000 after buying an additional 1,500 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Down 0.1%

LNTH opened at $60.82 on Thursday. The company’s 50-day moving average price is $56.10 and its two-hundred day moving average price is $63.23. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29. The stock has a market cap of $4.03 billion, a price-to-earnings ratio of 25.55 and a beta of -0.10. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The firm had revenue of $92.51 million for the quarter. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on LNTH shares. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the company a “neutral” rating in a research report on Wednesday, October 8th. Truist Financial reaffirmed a “hold” rating and set a $61.00 price objective (down from $63.00) on shares of Lantheus in a report on Monday, November 10th. Weiss Ratings downgraded shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. B. Riley dropped their price target on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research report on Tuesday, September 16th. Finally, TD Cowen reduced their price objective on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, September 15th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $74.17.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.